查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870081

爱迪生氏症检测市场：2025-2032年全球预测（按检测类型、最终用户、技术、分销管道、检体类型和患者年龄组划分）

Addison's Disease Testing Market by Test Type, End User, Technology, Distribution Channel, Sample Type, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，爱迪生氏症检测市场将成长至 3.6652 亿美元，复合年增长率为 4.05%。

关键市场统计数据
基准年 2024 2.6669亿美元
预计年份：2025年 2.7742亿美元
预测年份 2032 3.6652亿美元
复合年增长率 (%) 4.05%

爱迪生氏症检测处于内分泌学、实验室诊断和临床路径优化的关键交叉点。准确快速地识别原发性和续发性肾上腺皮质功能不全需要一系列诊断决策，涵盖生化检测、动态刺激通讯协定、影像学检查和临床解释。临床医师和实验室主任必须在确保病患舒适度和检测效率的前提下，妥善管理检测效能的变异性、分析前註意事项和鑑别诊断演算法。因此，肾上腺皮质功能不全的诊断策略越来越依赖整合的工作流程，将实验室检测与就地检验（如适用）和标靶影像学检查结合。

此外，诊断格局正受到不断变化的监管预期、支付方报销参数以及自动化平台普及的影响，这些因素正在改变实验室的处理能力和周转时间。这些因素影响医院、门诊机构和诊断实验室如何优先选择检测项目和分配资源。同时，研究机构正透过转化研究不断改进通讯协定，从而提高检测的特异性和灵敏度。综上所述，这些趋势要求临床团队、实验室管理人员和采购负责人协同应对，以确保检测流程在临床上保持稳健性，在营运上保持高效性，并与新出现的证据和政策变化保持一致。

技术应用、不断变化的法规、临床路径以及各机构与支付方的合作，共同推动了爱迪生氏症诊断的变革性变化。

近年来，诊断实践的变革性变化正在改变临床环境中对爱迪生氏症的检测、鑑别诊断和管理方式。技术创新，特别是自动化检测平台和改进免疫检测的广泛应用，提高了分析的一致性，并减少了人工操作时间。同时，就地检验的进步为分诊和快速临床决策创造了新的机会。此外，重新设计的临床路径强调对高风险族群肾上腺功能不全的早期识别，这促使检测流程和上游临床医生教育也需要进行相应调整。

2025年美国关税对爱迪生氏症检测供应链、采购趋势和跨境营运的累积影响

2025年美国关税政策的实施为诊断供应链和采购计画带来了新的变数，需要企业采取谨慎的策略应对措施。对进口试剂、仪器零件和辅助检测用品征收的关税提高了部分诊断用品的到岸成本，迫使实验室和经销商重新评估其筹资策略。为此，采购部门正在加快供应商资质审核，拓展供应商管道，并增加库存安全储备，以降低短期价格波动和延迟出货的风险。这些调整对资本规划和库存维修成本产生了连锁反应，尤其对议价能力有限的中小型实验室而言更是如此。

关键細項分析重点在于检测方法、终端用户环境、技术平台、通路、检体基质和患者人口统计特征之间的相互作用

详细的細項分析揭示了检测类型、终端用户环境、技术选择、通路、检体基质和患者人口统计特征如何共同影响诊断路径和操作优先顺序。在检测方法方面，ACTH刺激试验仍然是动态肾上腺评估的核心，而皮质醇测定则作为初步的生化筛检。地塞米松抑制通讯协定、标靶影像和胰岛素诱导低血糖试验通常具有特定的诊断功能，其作用取决于特定的临床状况或研究通讯协定。这些检测选择与终端使用者环境密切相关：门诊诊所和诊断实验室优先考虑快速出结果和工作流程效率；二级和三级医疗中心需要与住院诊疗路径相整合的高通量解决方案；而研究机构则优先考虑通讯协定的灵活性和方法的严谨性。

区域洞察：比较主要区域（美洲、欧洲、中东和非洲、亚太地区）的诊断准备、报销环境、供应链韧性和研究能力

区域趋势在决定诊断准备、报销框架和影响爱迪生氏症检测的研究投资方面发挥关键作用。在美洲，完善的实验室网路、一体化的通路和成熟的报销体系支援了各种生化检测和影像服务的广泛普及。然而，农村和资源匮乏地区仍然存在区域差异，因此需要有针对性地部署照护现场方案。在欧洲、中东和非洲地区，不同的法规环境和医疗基础设施导致了不同的应用模式。有些国家拥有整合的国家卫生系统和中心实验室，而有些国家则依赖私人或准公共诊断实验室，导致采购行为和供应链韧性的差异。

竞争考察重点在于创新轨迹、策略联盟、生产规模、监管合规和服务模式，这些因素共同塑造了诊断领域的领先地位。

诊断生态系统中的主要企业正利用技术创新、策略合作和规模优势相结合的方式，巩固其在肾上腺功能不全检测领域的地位。对检测方法改进和平台互通性的投入，既提升了分析性能，也提高了实验室整合效率。与临床网路、参考实验室和医疗设备製造商建立策略合作伙伴关係，能够整合互补能力，例如软体辅助的结果解读、整合检体处理和服务水准协议，从而增强产品价值提案。

为产业领导者提供切实可行的策略建议，以优化诊断服务、增强供应链韧性、协调报销策略并加速临床应用。

产业领导者可以采取多项具体措施，加强肾上腺功能不全的诊断服务，同时提升营运韧性和临床影响力。首先，优先协调实验室检测和就地检验检验，开发经验证的桥接研究和共用的临床决策支援工具，使临床医生无论在何处进行检测，都能对结果进行一致的解读。其次，积极与采购和支付相关人员沟通，透过以结果为导向的证据来证明其临床价值，并协商支持合理使用的报销机制。第三，透过对多家供应商进行资格认证、探索区域製造伙伴关係关係以及维持关键试剂和组件的策略储备，实现供应链多元化，从而降低贸易中断带来的风险。

一套透明的调查方法，概述了稳健的证据综合、二次检验、专家咨询、资料三角验证和品质保证的关键工作。

本分析的调查方法采用多层次证据综合分析法，以确保研究结果的透明度、可重复性和实用性。主要研究包括对临床内分泌学家、实验室主任、采购负责人和监管专家进行结构化访谈，以收集真实世界的营运洞察、临床决策驱动因素和政策考量。次要研究包括对同行评审文献、官方监管文件、临床指南和公司资讯披露进行系统性回顾，以阐明主要研究结果的背景，并识别检测开发、技术应用和供应链调整的趋势。

总结性发言，整合诊断趋势、政策意涵、细分市场动态、区域因素以及相关人员的策略要务。

总之，爱迪生氏症诊断体係正进入一个务实的演进阶段，技术进步、政策转变和供应链考量正在交会融合，重新定义临床实务。诊断准确性依赖于检测方法的精心整合，从皮质醇测量和刺激通讯协定到靶向成像，以及确保快速出具结果和可靠解读的操作流程。贸易措施和关税变化为采购和生产策略带来了新的考量，迫使各组织加强供应链韧性并重新评估采购模式。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新兴的唾液皮质醇检测方法可用于在基层医疗机构快速筛检爱迪生氏症（照护现场）
  • 液相层析法质谱联用技术在评估爱迪生氏症中用于精确测定皮质醇和促肾上腺皮质激素（ACTH）水平的应用日益广泛
  • 用于皮质醇和醛固酮定量分析的综合多重免疫检测的发展，可用于全面评估肾上腺功能不全
  • 穿戴式生化感测器持续追踪高风险爱迪生氏症患者的皮质醇波动
  • 将人工智慧驱动的预测分析整合到爱迪生氏症检测流程中，以优化早期检测和风险分层
  • 扩展的远端医疗家用采样套件，用于皮质醇刺激试验和患者肾上腺功能的长期监测
  • 一种新型合成短期刺激试验试剂盒获得监管部门核准，简化了肾上腺功能不全的诊断程序。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按检测类型分類的爱迪生氏症检测市场

  • ACTH刺激试验
  • 皮质醇测量
  • 地塞米松抑制试验
  • 影像诊断
  • 胰岛素诱导低血糖试验

第九章爱迪生氏症检测市场（依最终用户划分）

  • 门诊护理设施
  • 诊断实验室
  • 医院
    • 二级医疗机构
    • 三级医疗机构
  • 研究所

第十章 依技术分類的爱迪生氏症检测市场

  • 实验室
    • 自动化方法
    • 手工方法
  • 照护现场

第十一章爱迪生氏症检测市场（按分销管道划分）

  • 直销
  • 批发商
  • 线上销售

第十二章 依检体类型分類的爱迪生氏症检测市场

  • 血
    • 电浆
    • 血清
  • 唾液
    • 刺激唾液分泌
    • 全唾液
  • 尿

第十三章 依病患年龄层分類的爱迪生氏症检测市场

  • 成人
  • 老年人
  • 孩子们

第十四章爱迪生氏症检测市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章爱迪生氏症检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国爱迪生氏症检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Ortho Clinical Diagnostics, Inc.
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
    • Fujirebio Inc.
Product Code: MRR-B53D3ECDDA3A

The Addison's Disease Testing Market is projected to grow by USD 366.52 million at a CAGR of 4.05% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 266.69 million
Estimated Year [2025] USD 277.42 million
Forecast Year [2032] USD 366.52 million
CAGR (%) 4.05%

Addison's disease testing occupies a critical intersection between endocrinology, laboratory diagnostics, and clinical pathway optimization. Accurate, timely identification of primary and secondary adrenal insufficiency depends on a sequence of diagnostic decisions that span biochemical assays, dynamic stimulation protocols, imaging modalities, and clinical interpretation. Clinicians and laboratory leaders must navigate variability in test performance, pre-analytical considerations, and differential diagnostic algorithms while balancing patient comfort and operational throughput. As a result, diagnostic strategy for adrenal insufficiency increasingly relies on integrated workflows that combine laboratory-based assays with point-of-care screening and targeted imaging when indicated.

Moreover, the diagnostic landscape is shaped by evolving regulatory expectations, payer reimbursement parameters, and the proliferation of automated platforms that alter laboratory capacity and turn-around times. These forces influence how hospitals, ambulatory settings, and diagnostic laboratories prioritize test selection and resource allocation. At the same time, research institutes contribute to progressive refinement of protocols through translational studies that improve assay specificity and sensitivity. Taken together, these dynamics demand a coordinated response from clinical teams, laboratory managers, and procurement professionals to ensure that testing pathways remain clinically robust, operationally efficient, and aligned with emerging evidence and policy shifts.

Transformative shifts in Addison's disease diagnostics driven by technology adoption, regulatory evolution, clinical pathways, and payer engagement across sites

Recent transformative shifts in diagnostic practice are reshaping how Addison's disease is detected, characterized, and managed across clinical settings. Technological innovation, notably the spread of automated laboratory platforms and improved immunoassays, has increased analytical consistency and reduced hands-on time, while parallel advances in point-of-care testing have created new opportunities for triage and rapid clinical decision-making. At the same time, clinical pathway revisions that emphasize early recognition of adrenal insufficiency in at-risk populations are prompting adjustments in testing algorithms and upstream clinician education.

Concurrently, regulatory evolution and payer engagement are influencing test adoption and reimbursement dynamics. Regulators are clarifying performance standards and post-market surveillance expectations for diagnostic devices, which in turn shapes product development roadmaps and commercialization strategies. Payers are placing increasing emphasis on diagnostic stewardship and evidence-based utilization, encouraging providers to adopt tests that demonstrably improve clinical outcomes or reduce downstream costs. Finally, supply chain modernization and distributed manufacturing models are allowing diagnostics providers to rethink inventory strategies and resilience planning. These converging shifts require stakeholders to be agile: integrating new technologies into validated clinical workflows, engaging proactively with payers and regulators, and redesigning procurement approaches to manage both clinical demand and operational risk.

Cumulative impact of United States tariff measures implemented in 2025 on Addison's disease testing supply chains, procurement dynamics, and cross-border operations

The tariff measures enacted in the United States during 2025 introduced a new variable for diagnostic supply chains and procurement planning that merits careful strategic response. Tariffs applied to imported reagents, instrumentation components, and ancillary laboratory supplies have increased landed costs for some diagnostic inputs, prompting laboratories and distributors to reassess sourcing strategies. In response, procurement teams have accelerated supplier qualification efforts, diversified vendor bases, and increased inventory safety stocks to mitigate the risk of short-term price volatility and shipment delays. These adjustments have had knock-on effects on capital planning and inventory carrying costs, particularly for smaller laboratories with limited negotiating leverage.

Beyond procurement, tariffs have catalyzed operational reviews across manufacturing and distribution networks. Some domestic manufacturers have evaluated localizing production for high-volume reagents or spare parts to reduce exposure to cross-border tariff exposure, while international suppliers have explored tariff mitigation tactics such as tariff classification revisions and origin adjustments. Additionally, laboratories and healthcare systems have engaged more actively with payers and policy stakeholders to communicate the operational implications of import costs on testing access. Transitioning toward longer-term resilience, stakeholders are prioritizing contractual flexibility, exploring strategic partnerships with regional manufacturers, and instituting scenario planning to anticipate future trade policy shifts and minimize disruption to diagnostic service continuity.

Key segmentation insights revealing how test modalities, end-user settings, technology platforms, distribution pathways, sample matrices, and patient age cohorts interact

A nuanced segmentation analysis illuminates how test type, end-user context, technology choice, distribution pathway, sample matrix, and patient demographics collectively shape diagnostic pathways and operational priorities. Within test modalities, ACTH stimulation tests remain central to dynamic adrenal assessment while cortisol measurement assays function as initial biochemical screens; dexamethasone suppression protocols, targeted imaging, and insulin-induced hypoglycemia tests occupy more specialized diagnostic roles, often driven by specific clinical presentations or research protocols. These test choices interact closely with end-user settings: ambulatory care settings and diagnostic laboratories prioritize rapid turnaround and workflow efficiency, hospitals-both secondary and tertiary-require high-throughput solutions integrated with inpatient care pathways, and research institutes focus on protocol flexibility and methodological rigor.

Technology segmentation further differentiates capabilities. Lab-based platforms, including both automated and manual methods, support high-throughput processing and centralized quality controls, whereas point-of-care technologies enable decentralized screening and faster clinical action. Distribution channels influence availability and procurement cadence; direct sales relationships can streamline customization and service agreements, distributors provide breadth of product portfolios and logistics support, and online sales increase transactional accessibility for standardized consumables. Sample type considerations-blood with plasma and serum derivations, saliva in stimulated and whole formats, and urine matrices-affect pre-analytical protocols, assay selection, and patient experience. Finally, patient age group segmentation across adults, geriatrics, and pediatrics imposes different sensitivity requirements, sample volume constraints, and clinical interpretation frameworks. Taken together, these segmentation dimensions define distinct implementation footprints for diagnostic solutions and highlight where targeted investments will yield the greatest clinical and operational returns.

Regional insights that compare diagnostic readiness, reimbursement landscapes, supply chain resilience, and research capacity across major global regions including Americas EMEA and Asia-Pacific

Regional dynamics play a pivotal role in determining diagnostic readiness, reimbursement frameworks, and research investments that affect Addison's disease testing. In the Americas, established laboratory networks, consolidated distribution channels, and mature reimbursement ecosystems support broad access to a range of biochemical assays and imaging services, yet regional disparities in rural and resource-limited areas persist and require targeted deployment of point-of-care solutions. In Europe, Middle East & Africa, heterogeneous regulatory environments and variable healthcare infrastructure lead to distinct adoption patterns; some countries benefit from integrated national health systems and centralized reference laboratories, whereas others rely on private or semi-public diagnostic providers, which alters procurement behavior and supply chain resilience.

Asia-Pacific exhibits rapid capacity building and significant investments in laboratory modernization and local manufacturing, driving faster diffusion of automated platforms and molecular-grade reagents in key markets. However, country-level differences in reimbursement policies and clinical practice guidelines affect the pace of clinical adoption. Across each region, research capacity and clinical trial activity also vary, shaping the pipeline of evidence for newer diagnostic approaches. Consequently, stakeholders must align product development, distribution strategies, and clinician engagement with the specific regulatory, reimbursement, and infrastructure characteristics of each region to maximize diagnostic uptake and ensure equitable access.

Competitive company insights focusing on innovation trajectories, strategic partnerships, manufacturing scale, regulatory navigation, and service models shaping diagnostic leadership

Leading companies in the diagnostics ecosystem are pursuing a combination of technological innovation, strategic partnership, and operational scale to strengthen their positions in adrenal insufficiency testing. Investment in assay refinement and platform interoperability is enabling firms to deliver improved analytical performance alongside streamlined laboratory integration. Strategic partnerships with clinical networks, reference laboratories, and device manufacturers allow companies to combine complementary capabilities-such as software-enabled result interpretation, integrated sample handling, and service-level agreements-that enhance product value propositions.

Manufacturing scale and supply chain design remain critical differentiators. Firms that have invested in flexible production lines and regional manufacturing hubs can respond more quickly to demand shifts and mitigate cross-border trade exposures. Regulatory strategy is also central: companies with robust regulatory affairs capabilities expedite device clearances and maintain post-market compliance, which reinforces customer confidence. Service models that bundle diagnostics with consultative support, training, and data analytics create stickiness with end users and facilitate clinical adoption. Finally, targeted clinical evidence development-through investigator-initiated studies and collaborative research-continues to underpin long-term credibility and helps companies articulate clinical utility to payers, clinicians, and health system purchasers.

Actionable strategic recommendations for industry leaders to optimize diagnostics delivery, enhance supply resilience, align reimbursement strategies, and accelerate clinical adoption

Industry leaders can take several concrete actions to strengthen diagnostic delivery for adrenal insufficiency while improving operational resilience and clinical impact. First, prioritize harmonization between laboratory-based and point-of-care testing pathways by developing validated bridging studies and shared clinical decision-support tools, enabling clinicians to interpret results consistently regardless of testing venue. Second, engage proactively with procurement and payer stakeholders to demonstrate clinical value through outcomes-focused evidence and to negotiate reimbursement arrangements that support appropriate utilization. Third, diversify supply chains by qualifying multiple suppliers, exploring regional manufacturing partnerships, and maintaining strategic reserves for critical reagents and components to reduce vulnerability to trade disruptions.

In parallel, invest in workforce development and clinician education to improve test ordering practices and pre-analytical quality, thereby reducing diagnostic errors and repeat testing. Embrace digital solutions that integrate laboratory information systems with electronic health records to shorten turnaround times and provide richer contextual data for interpretation. Finally, pursue collaborative research with clinical centers and research institutes to generate real-world evidence that informs guideline development and supports payer conversations. By executing these targeted actions, organizations can enhance patient care, stabilize operations, and accelerate the adoption of reliable diagnostic approaches across diverse care settings.

Transparent research methodology outlining primary engagement, secondary validation, expert consultation, data triangulation, and quality assurance for robust evidence synthesis

The research methodology underpinning this analysis follows a multi-layered evidence synthesis approach designed to ensure transparency, reproducibility, and practical relevance. Primary research included structured interviews with clinical endocrinologists, laboratory directors, procurement professionals, and regulatory experts to capture real-world operational insights, clinical decision drivers, and policy considerations. Secondary research involved systematic review of peer-reviewed literature, public regulatory filings, clinical guidelines, and company disclosures to contextualize primary findings and to identify trends in assay development, technology adoption, and supply chain adaptations.

Data triangulation techniques were applied to reconcile disparate information sources and validate emergent themes, while quality assurance processes included cross-validation of interview inputs, methodological audits, and expert peer review. Where applicable, case studies were used to illustrate concrete examples of diagnostic pathway optimization, tariff mitigation strategies, and adoption of point-of-care solutions. The methodology also acknowledges limitations related to rapidly changing policy environments and market conditions; to address these, the analysis emphasizes strategic scenarios and adaptive practices rather than static predictions. Overall, the approach prioritizes actionable intelligence that stakeholders can apply to procurement decisions, clinical pathway redesign, and product development planning.

Conclusive perspectives that synthesize diagnostic trends, policy impacts, segmentation dynamics, regional considerations, and strategic imperatives for stakeholders

In conclusion, the diagnostic ecosystem for Addison's disease is entering a period of pragmatic evolution where technological advancement, policy shifts, and supply chain considerations converge to redefine clinical practice. Diagnostic accuracy depends on the thoughtful integration of test modalities-from cortisol measurement and stimulation protocols to targeted imaging-with operational processes that ensure timely results and reliable interpretation. Trade measures and tariff changes have introduced new considerations for procurement and manufacturing strategies, prompting organizations to enhance supply resilience and reassess sourcing models.

Segmentation and regional dynamics underscore that one-size-fits-all approaches are insufficient: test selection, distribution, and clinical implementation must be tailored to end-user capabilities, technology platforms, sample types, and patient cohorts. Companies that combine technological innovation with robust regulatory strategy, manufacturing flexibility, and collaborative evidence generation will be best positioned to support clinical adoption. Ultimately, stakeholders who adopt a proactive, integrated approach to diagnostics, supply chain management, and clinician engagement will improve patient outcomes while sustaining operational continuity in a dynamic policy and technology landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging point-of-care salivary cortisol assays enabling rapid Addison's disease screening in primary care settings
  • 5.2. Increasing adoption of liquid chromatography mass spectrometry for precise cortisol and ACTH profiling in Addison's evaluation
  • 5.3. Growth of multiplex immunoassays integrating cortisol and aldosterone quantification for comprehensive adrenal insufficiency assessment
  • 5.4. Emergence of wearable biochemical sensors tracking cortisol fluctuations continuously in at risk Addison's disease patients
  • 5.5. Integration of AI driven predictive analytics optimizing early detection and risk stratification in Addison's disease testing workflows
  • 5.6. Expansion of telehealth enabled home sampling kits for cortisol stimulation and long term monitoring of adrenal function in patients
  • 5.7. Regulatory approvals for novel synthetic short stimulation test kits streamlining adrenal insufficiency diagnostic procedures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Addison's Disease Testing Market, by Test Type

  • 8.1. Acth Stimulation Test
  • 8.2. Cortisol Measurement
  • 8.3. Dexamethasone Suppression Test
  • 8.4. Imaging
  • 8.5. Insulin-Induced Hypoglycemia Test

9. Addison's Disease Testing Market, by End User

  • 9.1. Ambulatory Care Settings
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals
    • 9.3.1. Secondary Hospitals
    • 9.3.2. Tertiary Hospitals
  • 9.4. Research Institutes

10. Addison's Disease Testing Market, by Technology

  • 10.1. Lab-Based
    • 10.1.1. Automated Methods
    • 10.1.2. Manual Methods
  • 10.2. Point-Of-Care

11. Addison's Disease Testing Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. Online Sales

12. Addison's Disease Testing Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Plasma
    • 12.1.2. Serum
  • 12.2. Saliva
    • 12.2.1. Stimulated Saliva
    • 12.2.2. Whole Saliva
  • 12.3. Urine

13. Addison's Disease Testing Market, by Patient Age Group

  • 13.1. Adults
  • 13.2. Geriatrics
  • 13.3. Pediatrics

14. Addison's Disease Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Addison's Disease Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Addison's Disease Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. F. Hoffmann-La Roche Ltd
    • 17.3.2. Abbott Laboratories
    • 17.3.3. Siemens Healthineers AG
    • 17.3.4. Danaher Corporation
    • 17.3.5. Thermo Fisher Scientific Inc.
    • 17.3.6. bioMerieux SA
    • 17.3.7. Ortho Clinical Diagnostics, Inc.
    • 17.3.8. DiaSorin S.p.A.
    • 17.3.9. Bio-Rad Laboratories, Inc.
    • 17.3.10. Fujirebio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ADDISON'S DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ADDISON'S DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ADDISON'S DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ACTH STIMULATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ACTH STIMULATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ACTH STIMULATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ACTH STIMULATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ACTH STIMULATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ACTH STIMULATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY CORTISOL MEASUREMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY CORTISOL MEASUREMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY CORTISOL MEASUREMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY CORTISOL MEASUREMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY CORTISOL MEASUREMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY CORTISOL MEASUREMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DEXAMETHASONE SUPPRESSION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DEXAMETHASONE SUPPRESSION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DEXAMETHASONE SUPPRESSION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DEXAMETHASONE SUPPRESSION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DEXAMETHASONE SUPPRESSION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DEXAMETHASONE SUPPRESSION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY INSULIN-INDUCED HYPOGLYCEMIA TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY INSULIN-INDUCED HYPOGLYCEMIA TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY INSULIN-INDUCED HYPOGLYCEMIA TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY INSULIN-INDUCED HYPOGLYCEMIA TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY INSULIN-INDUCED HYPOGLYCEMIA TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY INSULIN-INDUCED HYPOGLYCEMIA TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AMBULATORY CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AUTOMATED METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AUTOMATED METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AUTOMATED METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AUTOMATED METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AUTOMATED METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY AUTOMATED METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY MANUAL METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY MANUAL METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY MANUAL METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY MANUAL METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY MANUAL METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY MANUAL METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY POINT-OF-CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY POINT-OF-CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY POINT-OF-CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY POINT-OF-CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY POINT-OF-CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY POINT-OF-CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY STIMULATED SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY STIMULATED SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY STIMULATED SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY STIMULATED SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY STIMULATED SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY STIMULATED SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY WHOLE SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY WHOLE SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY WHOLE SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY WHOLE SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY WHOLE SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY WHOLE SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ADDISON'S DISEASE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY LAB-BASED, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY SALIVA, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE ADDISON'S DISEASE TESTING MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ADDISON'S DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ADDISON'S DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)

TABL